Cancer
Malignant Thyroid Gland Neoplasm
CI-CAN-00003251Explore in graph →
Top-level176 active trials10 approved drugs63 evidence items
Loading cancer entity…
Cancer
CI-CAN-00003251Explore in graph →
Clinical trials
790 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (65)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02145143 | Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study | completed | Early Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT03647657 | 177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer | completed | Early Phase 1 | 8 | University Hospital, Basel, SwitzerlandOTHER | 1 | Feb 10, 2022 |
| clinicaltrials |
| NCT00718770 | A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression | completed | Early Phase 1 | 10 | University of Colorado, DenverOTHER | 1 | Jan 17, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Jun 18, 2025source: clinicaltrials